- ADVERTISEMENT -NEW DELHI, July 30, 2026 (Reuters) – India has taken enforcement action against about 90% of inspected pharmaceutical facilities identified as high-risk under a nationwide quality drive, the drug regulator’s chief said, as authorities step up oversight following global scrutiny of Indian-made drugs. Since late 2022, regulators have conducted more than 960 risk-based inspections and audits. Around 860 resulted in enforcement action, ranging from stop-production orders and license suspensions to cancellations in the most serious cases, according to Drugs Controller General of India Rajeev Raghuvanshi. The enforcement comes as regulators oversee more than 10,000 manufacturing facilities and about 1 million pharmacies despite manpower constraints, increasing reliance on risk-based inspections and digital monitoring. The CDSCO is also piloting artificial intelligence tools that offer support such as generating pre-inspection checklists, recommending regulatory actions, drafting inspection reports and classifying manufacturing facilities according to risk levels.